SEATTLE, WA — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. KVA12123, Kineta’s novel VISTA blocking...
Latest News
SAN DIEGO – Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that a multiyear research grant from Luxembourg National Research Fund (FNR) and Cancer Foundation Luxembourg has been awarded to Doctor Anna Golebiewska Ph.D., co-leading...
SAN DIEGO – Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or are resistant to, current treatment regimens today announced topline data results from the newly-diagnosed adjuvant arm of its open-label, Phase 2 clinical study being conducted at the...
SAN DIEGO – Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has been activated...
CAMBRIDGE, Mass. — Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, presented the interim safety and efficacy results from its Phase 2 study of KP104 in complement inhibitor-naïve patients with PNH at the 2023 American Society of Hematology (ASH) Annual Meeting held in San...
HOUSTON, TX — Kiromic BioPharma, Inc. (OTCQB: KRBP) reports favorable early efficacy results from the first patient enrolled in the Phase 1 Deltacel-01 clinical trial with Deltacel™ for treating stage 4 metastatic non-small cell lung cancer (NSCLC). Favorable preliminary evidence demonstrates Deltacel’s efficacy in controlling the growth of NSCLC. Deltacel...
UNIVERSITY PARK, Pa. — Kissing bugs, or triatomine bugs, are the primary vector for Chagas disease, a major public health concern in Central and South America and even the southern United States. However, there aren’t many good treatment options available, which means that to stop the spread of the potentially life-threatening...
SANTA MONICA, Calif. –– Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in...
SANTA MONICA, Calif. – Kite, a Gilead Company (Nasdaq: GILD), announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The...
SANTA MONICA, Calif. – Kite, a Gilead Company (Nasdaq: GILD), announced today results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/2 study evaluating its chimeric antigen receptor (CAR) T-cell therapy Tecartus® (brexucabtagene autoleucel) in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)....